0 Table of Contents |
1 Introduction |
2 Evidence Profiles |
3 EvidenceVariable Profiles |
4 Group Profiles |
5 Citation Profiles |
6 ArtifactAssessment Profiles |
7 Composition Profiles |
8 Other Profiles |
9 Profiles |
10 Extensions |
11 Terminologies |
12 Examples |
13 Downloads |
14 Artifacts Summary |
14.1 Adaptation |
14.2 BaselineMeasureEvidence |
14.3 BaselineMeasureReport |
14.4 BookCitation |
14.5 BookPartCitation |
14.6 CertaintyOfEvidence |
14.7 Classification |
14.8 CohortDefinition |
14.9 Comment |
14.10 ComparativeBaselineMeasureEvidence |
14.11 ComparativeEvidence |
14.12 ComparativeEvidenceReport |
14.13 ComparativeEvidenceReportSubject |
14.14 ComparativeParticipantFlow |
14.15 ComparatorDefinition |
14.16 ComparatorGroup |
14.17 ComparatorOnlyEvidence |
14.18 Comparison |
14.19 CompositeRating |
14.20 DatabaseCitation |
14.21 DatabaseEntryCitation |
14.22 DataDictionary |
14.23 DatasetCitation |
14.24 DateAsRating |
14.25 EndpointAnalysisPlan |
14.26 EvidenceList |
14.27 EvidenceMap |
14.28 EvidenceR6 |
14.29 EvidenceReport |
14.30 EvidenceReportSubject |
14.31 EvidenceSynthesisEvidence |
14.32 ExposureDefinition |
14.33 ExposureGroup |
14.34 GroupAssignment |
14.35 GroupR6 |
14.36 Guideline |
14.37 InterventionOnlyEvidence |
14.38 JournalArticleCitation |
14.39 M11Report |
14.40 MetaanalysisEligibilityCriteria |
14.41 MetaanalysisOutcomeDefinition |
14.42 MetaanalysisStudyGroup |
14.43 NetEffectContribution |
14.44 NetEffectContributionList |
14.45 NetEffectContributions |
14.46 NetEffectEstimate |
14.47 NonComparativeEvidence |
14.48 OutcomeDefinition |
14.49 OutcomeImportance |
14.50 OutcomeList |
14.51 ParticipantFlow |
14.52 ParticipantFlowMeasure |
14.53 ParticipantFlowReport |
14.54 PreprintCitation |
14.55 Rating |
14.56 Recommendation |
14.57 RecommendationAction |
14.58 RecommendationEligibilityCriteria |
14.59 RecommendationJustification |
14.60 RecommendationPlan |
14.61 RiskOfBias |
14.62 SearchResults |
14.63 SearchStrategy |
14.64 SingleStudyEvidence |
14.65 SoaPlanDefinition |
14.66 SoftwareCitation |
14.67 StudyEligibilityCriteria |
14.68 StudyGroup |
14.69 SummaryOfFindings |
14.70 SummaryOfNetEffect |
14.71 SystematicReviewEligibilityCriteria |
14.72 SystematicReviewExcludedStudies |
14.73 SystematicReviewIncludedStudies |
14.74 VariableDefinition |
14.75 WebPageCitation |
14.76 ArtifactApprovalDate |
14.77 ArtifactAssessmentCompared |
14.78 ArtifactAssessmentDateAsRating |
14.79 ArtifactEffectivePeriod |
14.80 ArtifactLastReviewDate |
14.81 CharacteristicDescription |
14.82 CharacteristicDeterminedByExpression |
14.83 CharacteristicDeterminedByReference |
14.84 CharacteristicDurationDuration |
14.85 CharacteristicDurationRange |
14.86 CharacteristicInstancesQuantity |
14.87 CharacteristicInstancesRange |
14.88 CharacteristicMethod |
14.89 CharacteristicOffset |
14.90 CharacteristicTiming |
14.91 CharacteristicValueExpression |
14.92 CharacteristicValueUri |
14.93 CombinationMethod |
14.94 CombinationThreshold |
14.95 EvidenceVariableCategoryValueReference |
14.96 EvidenceVariableDefinition |
14.97 StatisticModelApplied |
14.98 StatisticModelExpression |
14.99 StatisticModelIncludeIf |
14.100 StatisticModelIntended |
14.101 StatisticModelValueCodeableConcept |
14.102 StatisticModelValueQuantity |
14.103 StatisticModelValueRange |
14.104 VariableDefinitionComparatorCategory |
14.105 VariableDefinitionRoleSubtype |
14.106 VariableDefinitionVariableRoleCode |
14.107 Evidence Variable Role Subtype Value Set |
14.108 Recommendation Justification Classifier Codes Value Set |
14.109 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) |
14.110 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. |
14.111 179899 |
14.112 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers. |
14.113 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. |
14.114 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. |
14.115 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. |
14.116 19967827 Wonder woman was Argentine and her real name was Evita. |
14.117 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. |
14.118 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. |
14.119 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. |
14.120 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. |
14.121 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. |
14.122 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. |
14.123 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). |
14.124 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. |
14.125 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. |
14.126 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer. |
14.127 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. |
14.128 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. |
14.129 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. |
14.130 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego. |
14.131 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character. |
14.132 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image. |
14.133 29357271 Using Hawkeye from the Avengers to communicate on the eye. |
14.134 29694275 A regressive formula of perversity: Wertham and the women of comics. |
14.135 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics. |
14.136 30467172 Finding my inner Wonder Woman. |
14.137 33395 |
14.138 34871555 What Can Wonder Woman Teach Radiologists? |
14.139 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. |
14.140 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst. |
14.141 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman. |
14.142 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version |
14.143 Anticoagulation for COVID-19 Combined RCTs in NEJM |
14.144 Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_16 |
14.145 Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_17 |
14.146 Bariatric_Surgery_RYGB_VSG_LAGB_BPD |
14.147 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
14.148 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group |
14.149 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group |
14.150 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group |
14.151 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group |
14.152 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century |
14.153 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century |
14.154 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation |
14.155 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) |
14.156 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version |
14.157 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) |
14.158 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19 |
14.159 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort |
14.160 CohortDefinition_At_least_2_risk_factors_for_stroke |
14.161 CohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery |
14.162 CohortDefinition_BMI_30_34_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery |
14.163 CohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery |
14.164 CohortDefinition_BMI_35_39_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery |
14.165 CohortDefinition_BMI_35_and_at_least_1_obesity_related_comorbidity |
14.166 CohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans |
14.167 CohortDefinition_BMI_criteria_for_ADA_surgery_recommendation |
14.168 CohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years |
14.169 CohortDefinition_Cardiovascular_event |
14.170 CohortDefinition_Heart_failure_based_on_Phenotypes |
14.171 CohortDefinition_Lower_BMI_criteria_for_ADA_surgery_consideration |
14.172 CohortDefinition_Nonfatal_myocardial_infarction |
14.173 CohortDefinition_Nonfatal_stroke |
14.174 CohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter |
14.175 CohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter_with_Ranges |
14.176 CohortDefinition_Proxy_criteria_for_surgical_candidates |
14.177 CohortDefinition_Severe_obesity |
14.178 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z |
14.179 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group |
14.180 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group |
14.181 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis |
14.182 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study) |
14.183 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study |
14.184 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study |
14.185 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study |
14.186 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study |
14.187 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study |
14.188 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014 |
14.189 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015 |
14.190 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016 |
14.191 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015 |
14.192 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008 |
14.193 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014 |
14.194 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013 |
14.195 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015 |
14.196 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013 |
14.197 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial |
14.198 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial |
14.199 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014 |
14.200 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial |
14.201 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial |
14.202 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014 |
14.203 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis |
14.204 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
14.205 ComparativeEvidenceReportSubject_Association_of_Bariatric_Surgery_vs_Medical_Obesity_Treatment_With_Long_term_Medical_Complications_and_Obesity_Related_Comorbidities_2018_Norwegian_Cohort |
14.206 ComparativeParticipantFlow: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial |
14.207 ComparatorDefinition_NOT_Bariatric_Surgery_RYGB_VSG_LAGB_BPD |
14.208 ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis |
14.209 ComparatorGroup_JAMA_2018_Norwegian_cohort_study_Control_cohort |
14.210 ComparatorGroup_Obese_patients_18_years_old_without_bariatric_surgery |
14.211 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study |
14.212 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis |
14.213 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study |
14.214 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study |
14.215 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study |
14.216 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study |
14.217 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16 |
14.218 Composite Rating of FOI 153881 for Project FOI 112280 |
14.219 Computable_Publishing_LLC |
14.220 COVID_19PneumoniaHospitalizedAdult |
14.221 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19 |
14.222 DatabaseCitation: Citation for FEvIR Platform |
14.223 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
14.224 DataDictionary: Measuring the Rate of Scientific Knowledge Transfer |
14.225 DataDictionary: phs003190 |
14.226 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes |
14.227 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban |
14.228 Delany-Moretlwe 2022 clinical trial |
14.229 EBMImplementationGuideProfile Value Set |
14.230 EGFR_45_59 |
14.231 Evidence Based Medicine on FHIR Implementation Guide Code System |
14.232 EvidenceList: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY) |
14.233 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis |
14.234 EvidenceMap: Bariatric Surgery Summary of Findings Example for GIN 2022 |
14.235 EvidenceReportSectionCode Value Set |
14.236 EvidenceReportSubject_Clinical_Outcomes_for_Effects_of_Bariatric_Surgery |
14.237 EvidenceVariableRoleSubtype Value Set |
14.238 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version |
14.239 ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin |
14.240 ExposureGroup_JAMA_2018_Norwegian_cohort_study_Surgery_cohort |
14.241 ExposureVariable: Age (as continuous variable) |
14.242 ExposureVariable: Body Mass Index (as continuous variable) |
14.243 ExposureVariable: pht013093.v1.p1 Age at diagnosis |
14.244 ExposureVariable: pht013093.v1.p1 RACE |
14.245 ExposureVariable: pht013093.v1.p1 SEX |
14.246 ExposureVariable: pht013093.v1.p1 SUBJECT_ID |
14.247 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE |
14.248 ExposureVariable: pht013094.v1.p1 BODY_SITE |
14.249 ExposureVariable: pht013094.v1.p1 IS_TUMOR |
14.250 ExposureVariable: pht013094.v1.p1 SAMPLE_ID |
14.251 ExposureVariable: pht013094.v1.p1 SAMPLE_USE |
14.252 ExposureVariable: pht013094.v1.p1 Source_Type |
14.253 GroupAssignment: Bariatric Surgery vs. no bariatric surgery |
14.254 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD) |
14.255 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo |
14.256 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment |
14.257 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone |
14.258 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment |
14.259 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis |
14.260 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes |
14.261 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study |
14.262 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study |
14.263 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study |
14.264 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study |
14.265 Investigator |
14.266 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA |
14.267 IV remdesivir 200 mg then 100 mg/day for 9 days |
14.268 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16 |
14.269 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes |
14.270 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort |
14.271 Justification for Recommendation: ADA Obesity Management Recommendation 8.16 |
14.272 Justification for Recommendation: ADA Obesity Management Recommendation 8.17 |
14.273 M11 Report Template Instructions |
14.274 MetaanalysisEligibilityCriteria_Mean_difference_in_HbA1c_effect_of_bariatric_surgery_in_type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis |
14.275 MetaanalysisOutcomeDefinition_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up |
14.276 MetaanalysisStudyGroup_Effect_Estimates_for_Mortality_at_14_days_from_COVID19_Remdesivir_vs_Placebo_RCTs |
14.277 Mortality at 14 days |
14.278 NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022 |
14.279 NetEffectContribution: All-cause mortality for Example for GIN 2022 |
14.280 NetEffectContribution: New onset depression for Example for GIN 2022 |
14.281 NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022 |
14.282 NetEffectContribution: Remission of diabetes for Example for GIN 2022 |
14.283 NetEffectContribution: Treatment with opioids for Example for GIN 2022 |
14.284 NetEffectContributionList: Bariatric Surgery Example for GIN 2022 |
14.285 NetEffectContributions_Bariatric_Surgery_Example_for_GIN_2022 |
14.286 NetEffectEstimate: Bariatric Surgery Example for GIN 2022 |
14.287 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities |
14.288 Organ support-free days |
14.289 Outcome Importance Rating 100 of All-cause mortality |
14.290 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke |
14.291 Outcome Importance Rating 5 of New onset depression |
14.292 Outcome Importance Rating 5 of Remission of diabetes |
14.293 Outcome Importance Rating 5 of Treatment with opioids |
14.294 Outcome Importance Rating 8 of Additional GI surgical procedure |
14.295 OutcomeDefinition_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control |
14.296 OutcomeDefinition_Diabetes_in_remission |
14.297 OutcomeDefinition_HbA1c_at_12_months |
14.298 OutcomeDefinition_HbA1c_at_24_months |
14.299 OutcomeDefinition_HbA1c_at_36_months |
14.300 OutcomeDefinition_HbA1c_at_60_months |
14.301 OutcomeDefinition_HbA1c_at_6_months |
14.302 OutcomeDefinition_New_onset_depression |
14.303 OutcomeDefinition_Nonfatal_myocardial_infarction_or_stroke |
14.304 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery |
14.305 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years |
14.306 OutcomeVariable: HbA1c at 12 months |
14.307 OutcomeVariable: HbA1c at 24 months |
14.308 OutcomeVariable: HbA1c at 36 months |
14.309 OutcomeVariable: HbA1c at 6 months |
14.310 OutcomeVariable: HbA1c at 60 months |
14.311 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up |
14.312 OutcomeVariable: New onset depression |
14.313 OutcomeVariable: Nonfatal myocardial infarction or stroke |
14.314 OutcomeVariable: Remission of diabetes |
14.315 OutcomeVariable_Additional_GI_surgical_procedure |
14.316 OutcomeVariable_All_cause_mortality |
14.317 OutcomeVariable_Treatment_with_opioids |
14.318 ParticipantFlow: 2018 Norwegian Cohort Excluded from Analysis |
14.319 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis |
14.320 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis |
14.321 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis |
14.322 ParticipantFlowMeasure: Dropout due to stopping intervention |
14.323 ParticipantFlowMeasure: Exclusion from analysis |
14.324 ParticipantFlowMeasure: Inclusion in analysis |
14.325 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill |
14.326 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill |
14.327 Placebo |
14.328 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16 |
14.329 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17 |
14.330 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint |
14.331 Recommendation Justification Code System |
14.332 Recommendation: ADA Obesity Management Recommendation 8.16 |
14.333 Recommendation: ADA Obesity Management Recommendation 8.16-adapted |
14.334 Recommendation: ADA Obesity Management Recommendation 8.17 |
14.335 Remdesivir |
14.336 Remdesivir_IV_200_mg_once_then_100_mg_once_daily_for_9_days |
14.337 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19 |
14.338 Risk Of Bias Type Value Set |
14.339 Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide |
14.340 SearchResults: PubMed search for Wonder Woman |
14.341 SearchStrategy_PubMed_and_Embase_search_for_van_Veldhuisen_2022_systematic_review |
14.342 SearchStrategy_PubMed_search_for_Wonder_Woman |
14.343 Severely_Obese_Adults_2018_Norwegian_Cohort |
14.344 SoaPlanDefinition: Follow-up assessment 3 months after study start |
14.345 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter |
14.346 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488 |
14.347 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study |
14.348 StudyEligibilityCriteria_Eligibility_Criteria_for_DIBASY_Trial |
14.349 StudyEligibilityCriteria_Obese_patients_18_years_old |
14.350 StudyGroup_Bariatric_Surgery_Trial_Enrollment_Group |
14.351 StudyGroup_DIBASY_Trial_Enrollment_Group |
14.352 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022 |
14.353 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022 |
14.354 SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer |
14.355 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer |
14.356 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer |
14.357 Therapeutic-dose anticoagulation with heparin |
14.358 Type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis |
14.359 WebPageCitation: A HEvKA Update Summary |